***Background.*** Rapid evaluation of antimicrobial susceptibility is of great clinical importance in the treatment of nosocomial *Pseudomonas aeruginosa* infections, which increasingly carry carbapenemases and metallo-β-lactamases. We developed a loop-mediated isothermal amplification (LAMP)-based assay to detect 6 β-lactamase genes (KPC, GES, NDM, IMP, VIM, and OXA-48). We evaluated this new assay using previously genotypically and phenotypically characterized clinical *P aeruginosa* isolates that were collected between 2004 and 2012 from diverse geographic locations including Argentina, Brazil, China, Colombia, Croatia, France, Germany, Greece, India, Philippine, Mexico, Romania, and Spain.

***Methods.*** The LAMP-based assay was evaluated using reference strains having each of 6 β-lactamase genes; including *Klebsiella pneumoniae*, *Escherichia coli*, *P aeruginosa*, and *Acinetobacter bereziniae*. A collection of 47 clinical *P aeruginosa* isolates, previously fully characterized by next-generation sequencing (NGS), were used for evaluation of our new LAMP method. The results were compared with those obtained using the conventional polymerase chain reaction (PCR) method.

***Results.*** The LAMP assay was able to detect as few as 10 copies of the gene in a sample, which was comparable to the conventional PCR method. The LAMP assay correctly detected β-lactamase genes in all collected clinical isolates (47 of 47). In contrast, PCR did not detect 4 IMP β-lactamase genes (IMP-4, 13, 15, and 18) in the clinical isolates (43 of 47). Among those PCR failed to detect, 1 isolate was susceptible to carbapenem and 3 were carbapenem-resistant isolates. Compared with the NGS results, the sensitivity and specificity of the IMP β-lactamase genes LAMP assay were 100% (4 of 4) and 100% (43 of 43), whereas those of the conventional PCR were 0% (0 of 4) and 100% (43 of 43).

***Conclusion.*** The established LAMP assay proved to be an appropriate tool for the detection of 6 different β-lactamase genes. The test demonstrated higher sensitivity and similar specificity compared with conventional PCR. The LAMP needs the minimum technology for the assay. The test would be useful for routine simple confirmation of β-lactamase producing *P aeruginosa*.
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